Cyclosporin A in orthotopic canine hepatic transplants

James W. Williams, Thomas G. Peters, Roger Haggitt, Stephen VanVoorst, William Hickerson, Richard Patterson, Robert Thompson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cyclosporin A, a potent yet selective immunosuppressant, does not appear to predispose to the infectious and metabolic complications seen with conventional immunosuppression. The purpose of this work is to determine the efficacy and dose requirements of Cyclosporin A in canine orthotopic hepatic transplantation and to assess potential toxicity in the hepatic allograft. Twenty dogs received orthotopic hepatic transplantation and survived 5 or more days postoperatively. Nine dogs received azathioprine 4-6 mg/kg, nine Cyclosporin A, 20 mg/kg incrementally decreased by 50% at 14 day intervals, and two dogs received no immunosuppression. Serial determinations of serum bilirubin, alkaline phophatase, WBC, Hgb, Hct, and serial percutaneous liver biopsies were performed. Average survival for the control dogs (no immunosuppression) was 11 days, the azathioprine group, 16.9 days, and the Cyclosporin A dogs, 37.7 days (P < 0.05). Liver function studies at 7, 14, and 21 days were remarkably preserved in the Cyclosporin A-treated group compared to the controls and azathioprine group. No histologic or biochemical evidence of rejection appeared until the daily dose of Cyclosporin A fell below 20 mg/kg. No histologic or biochemical evidence of renal or hepatic toxicity was evident in the Cyclosporin A-treated dogs. Cyclosporin A at 20 mg/kg was found to be efficacious in canine hepatic transplants with significantly improved survival and liver function compared to azathioprine.

Original languageEnglish (US)
Pages (from-to)576-585
Number of pages10
JournalJournal of Surgical Research
Volume32
Issue number6
DOIs
StatePublished - Jan 1 1982

Fingerprint

Cyclosporine
Canidae
Transplants
Liver
Azathioprine
Dogs
Immunosuppression
Liver Transplantation
Immunosuppressive Agents
Bilirubin
Allografts
Kidney
Biopsy
Control Groups
Serum

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Williams, J. W., Peters, T. G., Haggitt, R., VanVoorst, S., Hickerson, W., Patterson, R., & Thompson, R. (1982). Cyclosporin A in orthotopic canine hepatic transplants. Journal of Surgical Research, 32(6), 576-585. https://doi.org/10.1016/0022-4804(82)90142-1

Cyclosporin A in orthotopic canine hepatic transplants. / Williams, James W.; Peters, Thomas G.; Haggitt, Roger; VanVoorst, Stephen; Hickerson, William; Patterson, Richard; Thompson, Robert.

In: Journal of Surgical Research, Vol. 32, No. 6, 01.01.1982, p. 576-585.

Research output: Contribution to journalArticle

Williams, JW, Peters, TG, Haggitt, R, VanVoorst, S, Hickerson, W, Patterson, R & Thompson, R 1982, 'Cyclosporin A in orthotopic canine hepatic transplants', Journal of Surgical Research, vol. 32, no. 6, pp. 576-585. https://doi.org/10.1016/0022-4804(82)90142-1
Williams JW, Peters TG, Haggitt R, VanVoorst S, Hickerson W, Patterson R et al. Cyclosporin A in orthotopic canine hepatic transplants. Journal of Surgical Research. 1982 Jan 1;32(6):576-585. https://doi.org/10.1016/0022-4804(82)90142-1
Williams, James W. ; Peters, Thomas G. ; Haggitt, Roger ; VanVoorst, Stephen ; Hickerson, William ; Patterson, Richard ; Thompson, Robert. / Cyclosporin A in orthotopic canine hepatic transplants. In: Journal of Surgical Research. 1982 ; Vol. 32, No. 6. pp. 576-585.
@article{66b09f8d903b4129b27b902be423fbf5,
title = "Cyclosporin A in orthotopic canine hepatic transplants",
abstract = "Cyclosporin A, a potent yet selective immunosuppressant, does not appear to predispose to the infectious and metabolic complications seen with conventional immunosuppression. The purpose of this work is to determine the efficacy and dose requirements of Cyclosporin A in canine orthotopic hepatic transplantation and to assess potential toxicity in the hepatic allograft. Twenty dogs received orthotopic hepatic transplantation and survived 5 or more days postoperatively. Nine dogs received azathioprine 4-6 mg/kg, nine Cyclosporin A, 20 mg/kg incrementally decreased by 50{\%} at 14 day intervals, and two dogs received no immunosuppression. Serial determinations of serum bilirubin, alkaline phophatase, WBC, Hgb, Hct, and serial percutaneous liver biopsies were performed. Average survival for the control dogs (no immunosuppression) was 11 days, the azathioprine group, 16.9 days, and the Cyclosporin A dogs, 37.7 days (P < 0.05). Liver function studies at 7, 14, and 21 days were remarkably preserved in the Cyclosporin A-treated group compared to the controls and azathioprine group. No histologic or biochemical evidence of rejection appeared until the daily dose of Cyclosporin A fell below 20 mg/kg. No histologic or biochemical evidence of renal or hepatic toxicity was evident in the Cyclosporin A-treated dogs. Cyclosporin A at 20 mg/kg was found to be efficacious in canine hepatic transplants with significantly improved survival and liver function compared to azathioprine.",
author = "Williams, {James W.} and Peters, {Thomas G.} and Roger Haggitt and Stephen VanVoorst and William Hickerson and Richard Patterson and Robert Thompson",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0022-4804(82)90142-1",
language = "English (US)",
volume = "32",
pages = "576--585",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Cyclosporin A in orthotopic canine hepatic transplants

AU - Williams, James W.

AU - Peters, Thomas G.

AU - Haggitt, Roger

AU - VanVoorst, Stephen

AU - Hickerson, William

AU - Patterson, Richard

AU - Thompson, Robert

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Cyclosporin A, a potent yet selective immunosuppressant, does not appear to predispose to the infectious and metabolic complications seen with conventional immunosuppression. The purpose of this work is to determine the efficacy and dose requirements of Cyclosporin A in canine orthotopic hepatic transplantation and to assess potential toxicity in the hepatic allograft. Twenty dogs received orthotopic hepatic transplantation and survived 5 or more days postoperatively. Nine dogs received azathioprine 4-6 mg/kg, nine Cyclosporin A, 20 mg/kg incrementally decreased by 50% at 14 day intervals, and two dogs received no immunosuppression. Serial determinations of serum bilirubin, alkaline phophatase, WBC, Hgb, Hct, and serial percutaneous liver biopsies were performed. Average survival for the control dogs (no immunosuppression) was 11 days, the azathioprine group, 16.9 days, and the Cyclosporin A dogs, 37.7 days (P < 0.05). Liver function studies at 7, 14, and 21 days were remarkably preserved in the Cyclosporin A-treated group compared to the controls and azathioprine group. No histologic or biochemical evidence of rejection appeared until the daily dose of Cyclosporin A fell below 20 mg/kg. No histologic or biochemical evidence of renal or hepatic toxicity was evident in the Cyclosporin A-treated dogs. Cyclosporin A at 20 mg/kg was found to be efficacious in canine hepatic transplants with significantly improved survival and liver function compared to azathioprine.

AB - Cyclosporin A, a potent yet selective immunosuppressant, does not appear to predispose to the infectious and metabolic complications seen with conventional immunosuppression. The purpose of this work is to determine the efficacy and dose requirements of Cyclosporin A in canine orthotopic hepatic transplantation and to assess potential toxicity in the hepatic allograft. Twenty dogs received orthotopic hepatic transplantation and survived 5 or more days postoperatively. Nine dogs received azathioprine 4-6 mg/kg, nine Cyclosporin A, 20 mg/kg incrementally decreased by 50% at 14 day intervals, and two dogs received no immunosuppression. Serial determinations of serum bilirubin, alkaline phophatase, WBC, Hgb, Hct, and serial percutaneous liver biopsies were performed. Average survival for the control dogs (no immunosuppression) was 11 days, the azathioprine group, 16.9 days, and the Cyclosporin A dogs, 37.7 days (P < 0.05). Liver function studies at 7, 14, and 21 days were remarkably preserved in the Cyclosporin A-treated group compared to the controls and azathioprine group. No histologic or biochemical evidence of rejection appeared until the daily dose of Cyclosporin A fell below 20 mg/kg. No histologic or biochemical evidence of renal or hepatic toxicity was evident in the Cyclosporin A-treated dogs. Cyclosporin A at 20 mg/kg was found to be efficacious in canine hepatic transplants with significantly improved survival and liver function compared to azathioprine.

UR - http://www.scopus.com/inward/record.url?scp=0019955256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019955256&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(82)90142-1

DO - 10.1016/0022-4804(82)90142-1

M3 - Article

VL - 32

SP - 576

EP - 585

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 6

ER -